PATIENT INFORMATION LEAFLET
Montelukast ASTHMAPHARMA 5 mg chewable tablets EFG
Montelukast sodium
Read this leaflet carefully before you or your child start taking the medicine.
Montelukast is a leukotriene receptor antagonist that blocks certain substances called leukotrienes. Leukotrienes produce narrowing and swelling of the airways in the lungs. By blocking leukotrienes, Montelukast improves asthma symptoms and helps control asthma.
Your doctor has prescribed Montelukast to treat asthma and prevent asthma symptoms during the day and night.
The use of Montelukast will depend on your symptoms and the severity of your asthma or your child's asthma.
What is asthma?
Asthma is a chronic disease.
Asthma includes:
Asthma symptoms include: Coughing, wheezing, and congestion in the chest.
Inform your doctor about any allergy or medical condition you or your child have now or have had.
Do not take MONTELUKAST ASTHMAPHARMA if you or your child
Be especially careful with MONTELUKAST ASTHMAPHARMA
Use in children
For children aged 2 to 5 years, Montelukast 4 mg chewable tablets are available.
For children aged 6 to 14 years, Montelukast 5 mg chewable tablets are available.
Use of other medications
Some medications may affect the functioning of Montelukast, or Montelukast may affect the functioning of other medications you are using.
Inform your doctor or pharmacist if you or your child are using or have recently used other medications, including those obtained without a prescription.
Before taking Montelukast, inform your doctor if you or your child are taking the following medications:
Taking MONTELUKAST ASTHMAPHARMA with food and beverages
Montelukast 5 mg chewable tablets should not be taken with meals; they should be taken at least 1 hour before or 2 hours after meals.
Pregnancy and breastfeeding
Use during pregnancy
Women who are pregnant or intend to become pregnant should consult their doctor before taking Montelukast. Your doctor will evaluate whether you can take Montelukast during this period.
Use during breastfeeding
The presence of Montelukast in breast milk is unknown. If you are breastfeeding or intend to breastfeed, consult your doctor before taking Montelukast.
Driving and operating machinery
Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to the medication may vary.
Certain adverse effects (such as dizziness and somnolence) that have been reported very rarely with Montelukast may affect the patient's ability to drive or operate machinery.
Important information about some of the components of MONTELUKAST ASTHMAPHARMA
This medication may be harmful to individuals with phenylketonuria because it contains aspartame, which is a source of phenylalanine.
If your child has phenylketonuria (a rare hereditary metabolic disorder), be aware that each 5 mg chewable tablet of Montelukast contains phenylalanine (equivalent to 0.168 mg of phenylalanine in each 5 mg chewable tablet).
For children aged 6 to 14 years:
Take one chewable tablet of 5 mg daily at night. Montelukast should not be taken with meals; it should be taken at least 1 hour before or 2 hours after eating.
If you or your child are taking Montelukast Asthmapharma, ensure that neither you nor your child take any other product containing the same active ingredient, montelukast.
If you or your child take more Montelukast Asthmapharma than you should:
In most cases of overdose, no adverse effects were reported. The symptoms that occurred most frequently reported in overdose in adults and children were abdominal pain, drowsiness, drowsiness, headache, vomiting, and hyperactivity.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Montelukast Asthmapharma or forgot to give Montelukast Asthmapharma to your child:
Try to take Montelukast as prescribed. However, if you or your child forget a dose, simply resume the usual regimen of one tablet once a day.
Do not take a double dose to compensate for the missed doses.
If you or your child interrupt treatment with Montelukast Asthmapharma:
Montelukast can only treat your asthma or your child's asthma if you or your child continue to take it. It is essential to continue taking Montelukast for the time your doctor prescribes. It will help control your asthma or your child's asthma.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medications, Montelukast can produce side effects, although not everyone will experience them.
In clinical trials conducted with Montelukast 5 mg chewable tablets, the side effects related to the administration of the medication and reported most frequently (occurring in at least 1 in 100 patients and less than 1 in 10 patients treated), were:
In addition, the following side effects were reported in clinical trials with Montelukast 10 mg film-coated tablets:
These side effects were generally mild and occurred more frequently in patients treated with MONTELUKAST than with placebo (a tablet that does not contain medication).
In addition, since the medication has been marketed, the following side effects have been reported:
In patients with asthma treated with montelukast, rare cases of a combination of symptoms such as flu-like illness, tingling or numbness of arms and legs, worsening of pulmonary symptoms, and/or skin rash (Churg-Strauss syndrome) have been reported. Inform your doctor immediately if you have one or more of these symptoms. Rare cases (may affect up to 1 in 10,000 people) of stuttering have also been reported.
Ask your doctor or pharmacist for more information about side effects. If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, report it to your doctor or pharmacist.
Composition of MONTELUKAST ASTHMAPHARMA
Manitol, microcrystalline cellulose, sodium croscarmellose, L-hydroxypropyl cellulose, iron oxide red (E172), cherry aroma, aspartame (E 951), magnesium stearate.
Appearance of the product and contents of the package
The chewable tablets of Montelukast 5 mg are pink, round, biconvex, packaged in blister of PA/ALL/PVC-Aluminum in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 140, and 200 tablets.
Only some package sizes may be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
FARMALIDER S.A.
c/ Aragoneses 15-
28108 Alcobendas (Madrid)
Spain
Responsible for manufacturing
PHARMATEN, S.A.
6 Dervenakion Street
Pallini 15351 –Athens
Greece
or
PHARMATEN INTERNATIONAL, S.A.
Sapes Industrial Park Block 5
69300 Rodopi
Greece
or
FARMALIDER S.A.
c/ Aragoneses 15-
28108 Alcobendas (Madrid)
Spain
This leaflet was approved in March 2025
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.